These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3543613)

  • 21. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.
    Garvey WT; Olefsky JM; Griffin J; Hamman RF; Kolterman OG
    Diabetes; 1985 Mar; 34(3):222-34. PubMed ID: 3882489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulin-dependent diabetic parents.
    Gulli G; Rossetti L; DeFronzo RA
    Metabolism; 1997 Oct; 46(10):1157-61. PubMed ID: 9322799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.
    Simonson DC; Delprato S; Castellino P; Groop L; DeFronzo RA
    Diabetes; 1987 Feb; 36(2):136-46. PubMed ID: 3100365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
    Mizuno A; Kuwajima M; Ishida K; Noma Y; Murakami T; Tateishi K; Sato I; Shima K
    Metabolism; 1997 Jul; 46(7):745-9. PubMed ID: 9225826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
    Clore JN; Post EP; Bailey DJ; Nestler JE; Blackard WG
    J Clin Endocrinol Metab; 1992 Mar; 74(3):660-6. PubMed ID: 1740502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical correlates of basal hepatic glucose output and metabolic clearance rate of glucose using glucose-C-peptide-body mass indexes in ambulatory type 2 diabetic patients.
    Osei K; Holland GC
    Diabetes Res; 1987 Aug; 5(4):181-7. PubMed ID: 3665344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
    Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
    Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus.
    Henry RR; Brechtel G; Griver K
    J Clin Endocrinol Metab; 1988 May; 66(5):979-86. PubMed ID: 3283164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration.
    Katz H; Homan M; Jensen M; Caumo A; Cobelli C; Rizza R
    Diabetes; 1994 Feb; 43(2):289-96. PubMed ID: 8288053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Glucose tolerance, function of pancreatic B-cells and blood lipids in "healthy" offspring of parents with conjugal type 2 diabetes].
    Jaskólska-Ładosz K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R
    Pol Arch Med Wewn; 2000; 103(3-4):153-61. PubMed ID: 11236242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenic mechanism of type 2 diabetes in Ghanaians--the importance of beta cell secretion, insulin sensitivity and glucose effectiveness.
    Amoah AG; Owusu SK; Schuster DP; Osei K
    S Afr Med J; 2002 May; 92(5):377-84. PubMed ID: 12108171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose fluxes and oxidation after an oral glucose load in patients with non-insulin-dependent diabetes mellitus of variable severity.
    Féry F; Melot C; Balasse EO
    Metabolism; 1993 Apr; 42(4):522-30. PubMed ID: 8487677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes.
    Basu R; Basu A; Johnson CM; Schwenk WF; Rizza RA
    Diabetes; 2004 Aug; 53(8):2042-50. PubMed ID: 15277384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of gluconeogenesis after a 3-day fast does not deplete liver glycogen in patients with NIDDM.
    Clore JN; Blackard WG
    Diabetes; 1994 Feb; 43(2):256-62. PubMed ID: 8288050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.